Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
Avtorji:ID Khurshed, Mohammed (Avtor)
ID Aarnoudse, Niels (Avtor)
ID Hulsbos, Renske (Avtor)
ID Hira, Vashendriya V. V. (Avtor)
ID Laarhoven, Hanneke WM van (Avtor)
ID Wilmink, Johanna W (Avtor)
ID Molenaar, Remco J. (Avtor)
ID Noorden, Cornelis J. F. van (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.201800547R
 
.pdf PDF - Predstavitvena datoteka, prenos (1,49 MB)
MD5: 9A19264B3391250C1485FE6AE3EB5ADE
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo NIB - Nacionalni inštitut za biologijo
Povzetek:Isocitrate dehydrogenase (IDH1)-1 is mutated in various types of human cancer, and the presence of this mutation is associated with improved responses to irradiation and chemotherapy in solid tumor cells. Mutated IDH1 (IDH1MUT) enzymes consume NADPH to produce D-2-hydroxyglutarate (D-2HG) resulting in the decreased re ducing power needed for detoxification of reactive oxygen species (ROS), for example. The objective of the current study was to investigate the mechanism behind the chemosensitivity of the widely used anticancer agent cisplatin in IDH1MUT cancer cells. Oxidative stress, DNA damage, and mitochondrial dysfunction caused by cisplatin treatment were monitored in IDH1MUT HCT116 colorectal cancer cells and U251 glioma cells. We found that exposure to cisplatin induced higher levels of ROS, DNA double-strand breaks (DSBS), and cell death in IDH1MUT cancer cells, as compared with IDH1 wild-type (IDH1WT) cells. Mechanistic investigations revealed that cisplatin treatment dose dependently reduced oxidative respiration in IDH1MUT cells, which was accompanied by disturbed mitochondrial proteostasis, indicative of impaired mitochondrial activity. These effects were abolished by the IDH1MUT inhibitor AGI-5198 and were restored by treatment with D-2HG. Thus, our study shows that altered oxidative stress responses and a vulnerable oxidative metabolism underlie the sensitivity of IDH1MUT cancer cells to cisplatin.—Khurshed, M., Aarnoudse, N., Hulsbos, R., Hira, V. V. V., van Laarhoven, H. W. M., Wilmink, J. W., Molenaar, R. J., van Noorden, C. J. F. IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity. 32, 6344–6352 (2018). www.fasebj.org
Ključne besede:isocitrate dehydrogenase, chemosensitivity, cis-diamminedichloroplatinum, 2-hydroxyglutarate
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.11.2018
Leto izida:2018
Št. strani:str. 6344-6352
Številčenje:Vol. 32
PID:20.500.12556/DiRROS-19658 Novo okno
UDK:577
ISSN pri članku:0892-6638
DOI:10.1096/fj.201800547R Novo okno
COBISS.SI-ID:40468997 Novo okno
Datum objave v DiRROS:24.07.2024
Število ogledov:9
Število prenosov:5
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:The FASEB journal
Skrajšan naslov:FASEB J
Založnik:The Federation
ISSN:0892-6638
COBISS.SI-ID:25451520 Novo okno

Gradivo je financirano iz projekta

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Dutch Cancer Society
Številka projekta:KWF-UVA 2014–6839, AMC2016.1–10460
Naslov:Grants

Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:izocitrat dehidrogenaza, kemosenzibilnost, cis-diamminedichloroplatinum, 2-hidroksiglutarat


Nazaj